High rate of lymphoma patients respond to Bristol-Myers drug-study

December 6, 2014 6:01 PM

2 0

Dec 6 (Reuters) - Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday.

The study of Bristol-Myers' immunotherapy drug nivolumab involved 23 patients whose lymphoma had progressed after numerous prior treatments, including chemotherapy, stem cell transplants and the Seattle Genetics drug Adcetris.

Read more

To category page

Loading...